610 related articles for article (PubMed ID: 26974752)
1. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
3. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.
Deceuninck G; De Serres G; Boulianne N; Lefebvre B; De Wals P
Vaccine; 2015 May; 33(23):2684-9. PubMed ID: 25887086
[TBL] [Abstract][Full Text] [Related]
5. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
Domínguez Á; Ciruela P; Hernández S; García-García JJ; Soldevila N; Izquierdo C; Moraga-Llop F; Díaz A; F de Sevilla M; González-Peris S; Campins M; Uriona S; Martínez-Osorio J; Solé-Ribalta A; Codina G; Esteva C; Planes AM; Muñoz-Almagro C; Salleras L
PLoS One; 2017; 12(8):e0183191. PubMed ID: 28806737
[TBL] [Abstract][Full Text] [Related]
8. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
10. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
Wei SH; Chiang CS; Chiu CH; Chou P; Lin TY
Pediatr Infect Dis J; 2015 Mar; 34(3):e71-7. PubMed ID: 25247584
[TBL] [Abstract][Full Text] [Related]
11. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
[TBL] [Abstract][Full Text] [Related]
12. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
Tin Tin Htar M; van Den Biggelaar AHJ; Sings H; Ferreira G; Moffatt M; Hall-Murray C; Verstraeten T; Gessner BD; Schmitt HJ; Jodar L
Expert Rev Vaccines; 2019 Oct; 18(10):1069-1089. PubMed ID: 31585049
[No Abstract] [Full Text] [Related]
13. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
[TBL] [Abstract][Full Text] [Related]
18. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study.
Jayasinghe S; Chiu C; Quinn H; Menzies R; Gilmour R; McIntyre P
Clin Infect Dis; 2018 Jul; 67(3):367-374. PubMed ID: 29471432
[TBL] [Abstract][Full Text] [Related]
20. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
